Health Care·Biotechnology·$10.3B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.60 | N/A | -177.78% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.60 | N/A | -177.78% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management acknowledged the difficulties faced in the quarter. They emphasized their commitment to long-term strategies without offering specific guidance.
Management did not provide specific details on revenue expectations.
The company is focusing on long-term growth despite current challenges.
Arrowhead Pharmaceuticals reported a loss that was worse than expected, leading to a 4.48% drop in stock price. The lack of revenue data and guidance may raise concerns among investors about the company's short-term performance. Management's focus on long-term strategies suggests they are prioritizing future growth over immediate results.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
OTIS WORLDWIDE CORP
Jan 31, 2022